VEGFA and glioblastoma: Consistently, elevated levels of s-MCAM were observed in the plasma of glioblastoma patients treated with bevacizumab, i.e., anti-VEGF mAb, as well as in glioblastoma cells exposed to bevacizumab in vitro.